THE world's largest embryonic stem cell research programme could be given a new lease of life.
In 2011, biotech giant Geron announced that it was closing its stem cell programme, even though it had conducted a decade of research and treated four people in the first clinical trial of human embryonic stem cells (hESCs).
Now, Geron's former chief executive Thomas Okarma, and founder Michael West, have joined forces with a new subsidiary of BioTime, a biotech company based in Alameda, California. Together they have put forward a bid for Geron's stem cell assets in an effort to revive the programme.
Meanwhile, the four volunteers that received hESCs for spinal injuries are being monitored for adverse effects by the California Institute for Regenerative Medicine in San Francisco. "I'm happy to say that everything is still fine," says Kevin McCormack of CIRM, "which is a good sign for anyone buying the cell lines as it gives them a strong starting point for further clinical trials."
If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.
Have your say
Only subscribers may leave comments on this article. Please log in.
Only personal subscribers may leave comments on this article
Subscribe now to comment.
All comments should respect the New Scientist House Rules. If you think a particular comment breaks these rules then please use the "Report" link in that comment to report it to us.
If you are having a technical problem posting a comment, please contact technical support.
olbermann mega millions march 30 lucky numbers odds of winning mega millions mary mary sag aftra merger dj am
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.